CNS
-
以下是几个可能的英文标题： * Taysha Gene Therapies Announces Pricing for Public Offering of Common Stock and Pre-Funded Warrants * Taysha Gene Therapies Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants * Taysha Gene Therapies Reveals Pricing of Public Offering for Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (TSHA) announced a public offering to raise approximately $200 million. The offering includes common stock and pre-funded warrants, priced at $2.75 and $2.749 per share respectively. This capital will advance Taysha’s CNS-focused gene therapy programs, targeting diseases like Rett syndrome with its AAV-based therapies. The deal is expected to close around May 30, 2025.
